Skip to main content

Guido Ferrari, MD

Professor in Surgery
Research Professor in Molecular Genetics and Microbiology
Office: 915 S. Lasalle Street, Sorf Building Room 208, Durham, NC 27710
Campus Mail: DUMC Box 2926 Med Ctr, Durham, NC 27710

The activities of the Ferrari Laboratory are based on both independent basic research and immune monitoring studies. The research revolves around three main areas of interest: class I-mediated cytotoxic CD8+ T cell responses, antibody-dependent cellular cytotoxicity (ADCC), gene expression in NK and T cellular subsets upon infection with HIV-1. With continuous funding over the last 11 years from the NIH and Bill & Melinda Gates Foundation along with many other productive collaborations within and outside of Duke, the Ferrari Lab has expanded its focus of research to include the ontogeny of HIV-1 specific immune responses that work by eliminating HIV-1 infected cells and how these can be induced by AIDS vaccine candidates.

Education and Training

  • M.D., University of Genoa (Italy), 1985

Selected Grants

Publications

Mielke, Dieter, Sherry Stanfield-Oakley, Shalini Jha, Taylor Keyes, Adam Zalaquett, Brooke Dunn, Nicole Rodgers, et al. “Development of flow cytometry-based assays to assess the ability of antibodies to bind to SARS-CoV-2-infected and spike-transfected cells and mediate NK cell degranulation.” Cytometry A 101, no. 6 (June 2022): 483–96. https://doi.org/10.1002/cyto.a.24552.

Full Text

Gray, Matthew D., Junli Feng, Connor E. Weidle, Kristen W. Cohen, Lamar Ballweber-Fleming, Anna J. MacCamy, Crystal N. Huynh, et al. “Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain.” Sci Adv 8, no. 18 (May 6, 2022): eabm3948. https://doi.org/10.1126/sciadv.abm3948.

Full Text

DeGrace, Marciela M., Elodie Ghedin, Matthew B. Frieman, Florian Krammer, Alba Grifoni, Arghavan Alisoltani, Galit Alter, et al. “Defining the risk of SARS-CoV-2 variants on immune protection.” Nature 605, no. 7911 (May 2022): 640–52. https://doi.org/10.1038/s41586-022-04690-5.

Full Text

Li, Dapeng, Simon Brackenridge, Lucy C. Walters, Olivia Swanson, Karl Harlos, Daniel Rozbesky, Derek W. Cain, et al. “Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity.” Commun Biol 5, no. 1 (March 28, 2022): 271. https://doi.org/10.1038/s42003-022-03183-5.

Full Text

Gay, Cynthia L., Katherine S. James, Marina Tuyishime, Shane D. Falcinelli, Sarah B. Joseph, Matthew J. Moeser, Brigitte Allard, et al. “Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.” J Infect Dis 225, no. 5 (March 2, 2022): 856–61. https://doi.org/10.1093/infdis/jiab487.

Full Text

Curtis, Alan D., Pooja T. Saha, Maria Dennis, Stella J. Berendam, Pratamesh Ramasubramanian, Kaitlyn A. Cross, S Munir Alam, et al. “Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection.” Msphere 7, no. 1 (February 23, 2022): e0083921. https://doi.org/10.1128/msphere.00839-21.

Full Text

Wang, Shixia, Nicole L. Yates, Justin Pollara, Yegor Voronin, Sherry Stanfield-Oakley, Dong Han, Guangnan Hu, et al. “Broadly binding and functional antibodies and persisting memory B cells elicited by HIV vaccine PDPHV.” Npj Vaccines 7, no. 1 (February 9, 2022): 18. https://doi.org/10.1038/s41541-022-00441-9.

Full Text

Mielke, Dieter, Sherry Stanfield-Oakley, Bhavesh Borate, Leigh H. Fisher, Katelyn Faircloth, Marina Tuyishime, Kelli Greene, et al. “Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies.” J Virol 96, no. 2 (January 26, 2022): e0164321. https://doi.org/10.1128/JVI.01643-21.

Full Text

Mitchell, Julie L., Justin Pollara, Kenneth Dietze, R Whitney Edwards, Junsuke Nohara, Kombo F. N’guessan, Michelle Zemil, et al. “Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection.” J Clin Invest 132, no. 1 (January 4, 2022). https://doi.org/10.1172/JCI150937.

Full Text

Lakhashe, Samir K., Mario Amacker, Dinesh Hariraju, Hemant K. Vyas, Kyle S. Morrison, Joshua A. Weiner, Margaret E. Ackerman, et al. “Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges.” Front Immunol 13 (2022): 788619. https://doi.org/10.3389/fimmu.2022.788619.

Full Text

Pages